Aquestive Therapeutics
Milosz Blyszczek, PharmD, MBA, BCMAS, currently serves as the Director of Clinical Operations at Aquestive Therapeutics, managing study execution and overseeing various teams involved in clinical trials since April 2023. Prior experience includes roles as Adjunct Faculty at California Northstate University, where Milosz developed instructional materials for graduate pharmaceutical studies, and Senior Manager of Clinical Operations at Sirnaomics, Inc., focusing on CRO oversight and study management. Additional positions held include Operations Manager at Innovent Biologics, where responsibilities involved strategic oversight and document review, and various intern roles across healthcare settings that contributed to knowledge in pharmacotherapy and operational improvements. Milosz holds a PharmD from California Northstate University, an MBA from Sacramento State College of Business Administration, and a BA in Biology from Rutgers University.
Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117.